TD Cowen initiated coverage of Simulations Plus (SLP) with a Hold rating and $16 price target The firm says the company’s software and services biosimulation platform drives significant cost and time savings for its biopharma customers. TD is “constructive” on the outlook for Simulations’ software revenue growth, but says a customer spending slowdown in the company’s consulting services “looms large” while synergies from its restructuring initiatives will take time.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- S&P Dow Jones Indices announces quarterly rebalance
- Runway AI Expands Into Robotics Training With Nvidia and Alphabet Backing